An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
The results come amid feverish investor interest in drugs that can be used for weight loss. Shares of ... Several other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback